CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
ADENOVIRUS/PSA VACCINEbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00583024
NCT00583024Phase 2Completed
CompareCT.gov

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

David M Lubaroff·interventional·Posted Dec 31, 2007·Updated Apr 28, 2023

In Brief

A Phase 2 clinical trial evaluating ADENOVIRUS/PSA VACCINE for Hormone Refractory Prostate Cancer. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone Refractory Prostate Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 31, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 31, 2020
Study CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 13.1 yearsPosted 18.5 years ago

Interventions

ADENOVIRUS/PSA VACCINEbiological

1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60